TAX与GEM联合DDP治疗晚期非小细胞肺癌的临床观察

目的观察紫杉醇联合顺铂(TP方案)及吉西他滨联合顺铂(GP方案)治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副作用。方法将84例晚期NSCLC患者随机分成TP组和GP组,入组的患者均接受至少2周期TP和GP的治疗方案,比较两组治疗方案的临床疗效和毒副作用。结果 TP组和GP组的化疗有效率分别为42.9%(18/42)和38.1%(16/36),临床获益率分别为83.3%(35/42)和78.6%(33/42),中位生存期分别294 d和288 d,1年生存率、3年生存率分别为37.3%、9.6%和40.5%、10%,两组比较差异均无统计学意义(P>0.05);主要的毒副作用为骨髓抑制及恶心、呕吐,均可耐受。结论两组治疗方案对晚期NSCLC均有较好的疗效,TP和GP方案可作为晚期NSCLC的一线化疗方案。

Efficacy and Toxicities of Paclitaxel with Cisplatinin and Gemcitabine with Cisplatinin for Advanced Non-Small Cell Lung Cancer

Objective To evaluate the efficacy and toxicities of Paclitaxel plus Cisplatin(DDP)(TP) and Gemcitabine(GEM) plus Cisplatinin(GP) in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods Eighty four patients with advanced NSCLC were randomized into two groups(TP group and GP group).All patients accepted at least 2 cyclical chemotherapies with TP or GP.Therapeutic effect and side-effects of two groups were observed.Results The response rates and clinical benefit rates in the TP group and in the GP group were 42.9%(18/42) and 83.3%(35/42),38.1%(16/36) and 78.6%(33/42),respectively.The median survival time,1-year survival rate and 3-year survival rate were 294 days,37.3% and 9.6%,288 days,40.5% and 10% in the TP group and in the GP group,respectively.No significant difference was seen between two groups(P>0.05).The most common toxic and side-effects in two groups were hypoplasia of bone marrow and digestive tract reaction.Conclusion The TP and GP protocol have a similar efficacy,and can be chosen as the first chemotherapy protocols in treating patients with advanced NSCLC.